Literature DB >> 7899539

A subtle disturbance in the feedback regulation of the hypothalamic-pituitary-adrenal axis in the early phase of Alzheimer's disease.

B Näsman1, T Olsson, M Viitanen, K Carlström.   

Abstract

In an attempt to find if a disturbance in the function of the feedback regulation of the hypothalamic-pituitary-adrenal axis is an early feature in Alzheimer's disease (AD), 35 outpatients (mean age 76.8 years) with a mild to moderate AD were compared to 20 controls (mean age 73.8 years) in their response to different doses of dexamethasone. After 0.5 mg dexamethasone, serum cortisol levels were significantly less suppressed in patients with early AD (p = .03) and these patients were significantly more often dexamethasone nonsuppressors (serum cortisol > or = 138 nmol/l) than controls (14/35 vs. 2/20; p = .03). Nonsuppression to 1 mg dexamethasone did not differ between groups (2/35 vs. 0/20). Plasma adrenocorticotropin levels were significantly lower in patients with Alzheimer's disease (n = 16) after 0.5 mg as well as after 1.0 mg dexamethasone (p = .01 and p < .001, respectively). The relationship between cortisol resistance to dexamethasone suppression and pathophysiology of AD is discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7899539     DOI: 10.1016/0306-4530(94)00054-e

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  11 in total

1.  Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease.

Authors:  Kim N Green; Lauren M Billings; Benno Roozendaal; James L McGaugh; Frank M LaFerla
Journal:  J Neurosci       Date:  2006-08-30       Impact factor: 6.167

2.  3xTg-AD mice exhibit an activated central stress axis during early-stage pathology.

Authors:  Elaine K Hebda-Bauer; Tracy A Simmons; Andrew Sugg; Eren Ural; James A Stewart; James L Beals; Qiang Wei; Stanley J Watson; Huda Akil
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

3.  Subchronic glucocorticoid receptor inhibition rescues early episodic memory and synaptic plasticity deficits in a mouse model of Alzheimer's disease.

Authors:  Fabien Lanté; Magda Chafai; Elisabeth Fabienne Raymond; Ana Rita Salgueiro Pereira; Xavier Mouska; Scherazad Kootar; Jacques Barik; Ingrid Bethus; Hélène Marie
Journal:  Neuropsychopharmacology       Date:  2015-01-27       Impact factor: 7.853

Review 4.  Effects of stress and stress hormones on amyloid-beta protein and plaque deposition.

Authors:  Hongxin Dong; John G Csernansky
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

5.  Neurosteroids and GABA-A Receptor Function.

Authors:  Mingde Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2011-10-04       Impact factor: 5.555

Review 6.  Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases?

Authors:  Xin Du; Terence Y Pang
Journal:  Front Psychiatry       Date:  2015-03-09       Impact factor: 4.157

7.  Targeting glucocorticoid receptors prevents the effects of early life stress on amyloid pathology and cognitive performance in APP/PS1 mice.

Authors:  Sylvie L Lesuis; Sascha Weggen; Sandra Baches; Paul J Lucassen; Harm J Krugers
Journal:  Transl Psychiatry       Date:  2018-03-01       Impact factor: 6.222

Review 8.  The relationship between stress and Alzheimer's disease.

Authors:  Nicholas J Justice
Journal:  Neurobiol Stress       Date:  2018-04-21

9.  Positive and negative early life experiences differentially modulate long term survival and amyloid protein levels in a mouse model of Alzheimer's disease.

Authors:  Sylvie L Lesuis; Herve Maurin; Peter Borghgraef; Paul J Lucassen; Fred Van Leuven; Harm J Krugers
Journal:  Oncotarget       Date:  2016-06-28

Review 10.  Vulnerability and resilience to Alzheimer's disease: early life conditions modulate neuropathology and determine cognitive reserve.

Authors:  Sylvie L Lesuis; Lianne Hoeijmakers; Aniko Korosi; Susanne R de Rooij; Dick F Swaab; Helmut W Kessels; Paul J Lucassen; Harm J Krugers
Journal:  Alzheimers Res Ther       Date:  2018-09-19       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.